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Abstract
For the second time, the HIV Cure Research Center (HCRC) at Ghent University organised the HIV Cure and Reservoir
Symposium, in Ghent, Belgium, where in this two-day conference, virologists, molecular biologists, immunologists and
clinicians presented the most recent achievements in the field of HIV cure, including data on therapeutic vaccines, HIV
remission strategies such as ‘shock and kill’ or ‘block and lock’, benefits of early ART and potential of haematopoietic
stem cell transplant in achieving cure. Furthermore, methods to characterise and quantify the HIV reservoir were discussed
along with HIV reservoir characterisation in different body parts, including the central nervous system. An HIV activist
and representative of a patients‘ agency also presented the patients‘ perspective on HIV cure. This report is a summary
of all topics discussed during this symposium.
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Introduction
Professor Linos Vandekerckhove and Dr Magdalena Sips organised
the HIV Cure and Reservoir Symposium, 11–12 September 2017,
in Ghent, Belgium. More than 100 participants from 15 countries
were present to discuss the latest developments in HIV cure
approaches, and the presence ofmany experts in the field facilitated
high-level discussions: GuidoVanham (Institute ofTropicalMedicine,
Antwerp, Belgium); Beatriz Mothe (IrsiCaixa, Spain); Ole Søgaard
(Aarhus University Hospital, Skejby, Denmark); Jintanat
Ananworanich (US Military HIV Research Program, USA); Magnus
Gisslén (University of Gothenburg, Sweden); Asier Sáez-Cirión
(Institute Pasteur, France); Maria Buzon (Vall d‘Hebron Institut
de Recerca, Spain); Philip Goulder (University of Oxford, UK); Carine
van Lint (ULB, University of Brussels, Belgium); Zeger Debyser
(KU Leuven, Belgium); Sabine Kinloch (Royal Free London, UK);
and Stephane De Wit (St Pierre University Hospital, Belgium). The
scientific committee, comprising LinosVandekerckhove,Magdalena
Sips and Maria Buzon, selected the best submitted abstracts for
oral and poster presentations. An overview of the programme,
including invited and selected presentations at the symposium, is
depicted in Table 1. This symposium was directly followed by a
three-day HIV Reservoir Characterization Workshop, which aimed
to provide the participants with a thorough understanding of HIV
quantification tools, including PCR-based and cell-based functional
assays, which are of great importance in therapy monitoring, for
the development of HIV cure strategies. In addition to virological
assays, theworkshop presented an overview of immunological assays
that are commonly used to assess the potency of both the cellular
and humoral immune system. The workshops included theory
sessions, hands-on practical sessions and data analysis training.
Session 1
Following the inauguration of the symposium by Professor Linos
Vandekerckhove, where the critical issues in the search for an
HIV cure were discussed, the symposium was opened byMr Fred
Verdult, a representative of a patients‘ communication agency,
Volle Maan, who talked about the patient perspective on HIV cure,
and presented intriguing differences between scientists‘ and patients‘
views of why an HIV cure is needed. According to HIV scientists
questioned during a conference in 2011, themost important reasons
to find an HIV cure are: to prolong life expectancy, to eliminate
long-term side effects, to erase the pill burden and financial reasons.
However, from 457 HIV-positive patients questioned, 94%
considered finding a cure important, but prolonging life expectancy
is only the ninthmost important reason from the patient perspective.
Side effects fromHIVmedication are the fifthmost important reason
to find a cure, and the pill burden ranks seventh, while financial
considerations are not in the top-ten reasons at all. For patients,
the most important reasons to find an HIV cure are long-term side
effects from infection and treatment, which have an overall negative
impact on general health. Importantly, patients consider
infectiousness and stigmatisation as the third and fourth most
important reasons why an HIV cure is needed. Social and emotional
disadvantages, not important for scientists, appear to be very
important from the patients‘ point of view, and the negative impact
on relationships, and living with a secret, are the eighth and tenth
most important drivers towards an HIV cure.
Following the opening talk, Professor Guido Vanham initiated
the scientific sessions of the symposium, and provided an overview
of state-of-the-art therapeutic vaccinations in HIV-infected
patients on combination antiretroviral therapy (cART). The
presentation reviewed different vaccination strategies based on
properties of the vaccine antigen: (a) vaccines focusing on the
most conserved parts of the HIV genome (Vacc4x of the
Scandinavian consortium and HIVconsv of the University of Oxford);
(b) vaccines combining the most representative ‘potential T cell
epitope’ (PTE) variants (mosaic vaccines); and (c) vaccines with
epitopes associated with evidence of in vivo protective T cell
responses (HIVACAT-T cell immunogen, HTI, IrsiCaixa) [1-8]. He
presented data showing that: Vacc4x induced a slight reduction
of the viral set point after analytical treatment interruption (ATI),
and that the vaccine in combination with romidepsin slightly
reduced the viral reservoir; HIVconsv can induce CD8 T cell HIV
suppressive capacity, and when combined with romidepsin, delays
the viral rebound after ATI; mosaic vaccine in rAd26 vector,
increases the breadth and depth of CD4+ and CD8+ T cell
responses, and as adeno primed with Env protein boost, is
considered a potent prophylactic vaccine when tested in monkeys;
HTI therapeutic vaccination induces T cell responses associated
with in vivo and in vitro CD8+ T cell-mediated HIV suppression.
Lastly, Professor Vanham addressed novel concepts in vaccinology,
such as mRNA vaccines, intranodal administration of vaccines and
combinations with anti-latency treatment or checkpoint inhibitors.
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Dr Beatriz Mothe reviewed the latest HIV therapeutic vaccine
trials conducted in patients who started cART within 6 months
after infection. In the BCN01 trial (NCT 01712425), 24 patients
were vaccinated with two different vaccination schemes (12
vaccinated long arm, with 24 weeks between prime and boost,
and 12 vaccinated short arm, with 8 weeks between prime and
boost), and 24 patients received a placebo [3,9].The vaccine regimen
is a HIVconsv vaccine, which was constructed by assembling the 14
most conserved regions of the HIV proteome into one chimeric
protein. The vaccine comprises a prime with an attenuated
chimpanzee adenovirus serotype 63 (ChAd63) and a boost with
a modified vaccinia virus Ankara (MVA), both encoding HIVcons.
After MVA boost, the subdominant responses to HIVconsv were
effectively boosted in both vaccination schemes. Reactivation was
not observed during peak immunogenicity, and the decay of proviral
DNA was similar to early-treated but not vaccinated individuals.
Some 15 out of 24 vaccinated patients from BCN01 were enrolled
into a subsequent roll-over study (BCN02-Romi), in which the
patients received a booster MVA vaccine followed by three doses
of romidepsin [10]. Dr Mothe described the main findings about
the immunogenicity and viral reservoir changes in these 15 patients.
Finally, participants who showed positive
immune response to the vaccine were invited
to undergo an ATI. Fourteen patients
underwent an ATI, and five of them showed
a late viral rebound (>4 weeks, up to 8
months), while the other nine demonstrated
a fast rebound.
Professor Ole Søgaard presented some of
the emerging data using the shock-and-kill
strategy, which aims to reduce the viral
reservoir in individuals living with HIV. After
introducing the concepts of sterilising and
functional cure, Professor Søgaard presented
data from trials using the following cure
strategies: reactivate the latent HIV reservoir;
enhance HIV-specific immunity; and enhance
innate immunity. Different latency-reversing
agents (LRA) (panobinostat, romidepsin,
disulfiram, vorinostat) have been shown to be
potent in reactivating part of the latent HIV
reservoir; however, development of more
potent LRAs has been suggested as an
important step to move this strategy
forward. Next, Dr Søgaard discussed
immunotherapeutic approaches that could
enhance the killing of the reservoir, showing
results of: (a) immune checkpoint blockade
with antibodies against PD1/PD-L1 or
CTLA4; (b) HIV broadly neutralising
antibodies (bNAb); (c) chimeric antigen
receptor (CAR) T cells; and (d) TLR7/9-
mediated immune activation. Finally, he
presented data from the BCN02-Romi trial,
which used combinations of LRAs with a
therapeutic vaccine as a shock-and-kill
strategy, previously discussed by Dr Mothe.
In the following oral abstract talk, Ms
Gerlinde Vansant presented a completely
different and opposite HIV cure strategy:
block and lock. LEDGINs, novel allosteric HIV
integrase (IN) inhibitors that target the lens
epithelium-derived growth factor (LEDGF)/
p75 binding pocket of IN, act as mediators
of the block-and-lock strategy and are
capable of blocking the establishment of a reactivation-competent
reservoir by redirecting the integration of HIV into silent regions,
resulting in inability of HIV to reactivate and therefore affording
a functional cure. She demonstrated that LEDGINs are capable
of inducing an integration shift out of the transcription units, and
as a result, increase the latent fraction of the reservoir and hamper
reactivation in cell lines.
Dr Sophie Bouchat showed the results of her research towards
the identification of UHRF1, a new factor involved in DNA
methylation-mediated repression of latent HIV. UHRF1 is involved
in HIV latency via a DNA methylation-mediated silencing
mechanism: it interacts with de novo methyl transferases and, as
such, increases methylation and mediates epigenetic silencing of
the HIV viral promoter region. These results suggest that UHRF1
might constitute a new potential molecular target for HIV cure
therapeutic strategies.
The last speaker of the day,Ms Michaela Madlenakova, showed
novel data implicating use of haem-arginate (HA) as a new
latency-reversing agent for HIV cure. HA potentiates PMA-
stimulated reactivation of HIV provirus in latently infected ACH-2
Table 1. HIV Cure and Reservoir Symposium 2017 programme
Speaker Subject
Linos Vandekerckhove Inauguration
Fred Verdult Patient perspective on HIV cure
Guido Vanham HIV cure efforts in Europe
Beatriz Mothe Therapeutic vaccine in early treated cohorts
Ole Søgaard Early lessons from shock and kill trials
Gerlinde Vansant Towards a block-and-lock strategy: LEDGINs hamper the
establishment of a reactivation competent reservoir
Sophie Bouchat Identification of a new factor involved in DNA methylation-
mediated repression of latent HIV-1
Michaela Madlenakova Heme-arginate as a latency reversing agent for HIV-1 cure
Jintanat Ananworanich Early ART and HIV remission
Alessandra Bandera Early start of antiretroviral therapy (ART) during primary HIV
infection (PHI) is associated with faster optimal
immunological recovery: results of Italian Network of ACuTe
HIV InfectiON (INACTION) retrospective study
Clarissa Van Hecke The expression profile of host restriction factors in different
cohorts of HIV-1-infected patients
Magnus Gisslén Defining the CNS HIV reservoir by CSF and blood biomarkers
Marie-Angélique De
Scheerder
CSF inflammatory profile in patients undergoing analytical
treatment interruption
Asier Sáez-Cirión Bone marrow transplantation in the IciStem consortium
Linos Vandekerckhove ABX464 decreases total HIV DNA in PBMCs when
administered during 28 days to HIV-infected patients who
are virologically suppressed
Inge De Lepeleire Single doses as low as 0.5 mg of the novel NRTTI MK-8591
suppress HIV for at least 7 days
Maria Buzon New assays to measure the latent HIV reservoir
Pieter Pannus Does viral suppressive capacity in cART-treated HIV-infected
patients correlate with disease parameters, viral reservoir
measures or cytotoxic T cell phenotype?
Basiel Cole Integration site detection in 10 chronically infected patients
Sofie Rutsaert Defining a total HIV DNA threshold as guidance for therapy
simplification strategies
Philip Goulder HIV cure/remission in paediatric infection
Jean-Christophe Beghin Immunovirological outcome of HIV-infected children living in
a resource-limited setting of South Africa
Linos Vandekerckhove Closing remarks
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cells, and stimulates HIV expression in peripheral blood
mononuclear cells (PBMCs) infected ex vivo. This reactivation is
mediated by haem or iron-induced redox stress. In patients, HA
Normosang induced reactivation of HIV, and subsequently a
reduction in the HIV reservoir size.
Session 2
Professor Jintanat Ananworanich opened the second day of the
symposium discussing the impact of early cART on HIV remission.
She presented data from the acute RV254 study and related HIV
remission trials. In the RV254 trial, 488 acutely infected patients
(Fiebig stages I–V) from cohorts in Thailand were enrolled and
placed immediately on cART. Such immediate cART initiation is
expected to induce low viral reservoir establishment and effective
immune restoration. Reservoir quantification was performed in
blood, sigmoid colon and lymph nodes (LN), and revealed that
the lowest total HIV DNA was detected in patients treated in Fiebig
stage I, while no difference in reservoir size was detected after
ART administration in Fiebig stages II–V. After Fiebig I, almost
all LN samples during acute infection showed detectable HIV DNA.
The median time to viral rebound during ATI, characterised by viral
load (VL) >20 copies/mL, was 26 days (range 13–48 days) in
Fiebig I treated individuals. Similar viral sequences between acute
infection and post rebound suggest that VL rebound was due to
clonal expansion of latently infected cells. Pre-ATI HIV DNA levels
were not significantly associated with time to VL rebound. Owing
to early treatment, effector CD8+ T cell immune responses
expanded only after VL rebound.
Dr Alessandra Bandera evaluated the clinical and epidemiological
characteristics of patients with acute HIV infection (Italian Network
of ACuTe HIV InfectiON ‘INACTION’ retrospective study) and
compared the effect of early versus late cART on virological
suppression, discontinuation of the first cART regimen and
immunological recovery (CD4 cell count, CD4% and CD4:CD8
ratio). She demonstrated that early cART initiation and a more
preserved immunological status at presentation are predictors of
optimal immunological recovery.
Ms Clarissa Van Hecke presented a study where the expression
profile of host restriction factors was examined in different cohorts
of HIV-infected patients: recent seroconverters, long-term non
progressors (LTNP), cART-naïve non-controllers, early- and
late-treated patients. Restriction factors APOBEC3G, SAMHD1,
SLFN11 and BST2/tetherin were significantly upregulated in early-
compared to late-treated HIV patients, suggesting that elevated
expression of these restriction factors could be beneficial for
maintaining host immunity. Unlike other restriction factors, SLFN11
was upregulated in LTNP and its expression was negatively
correlated with integrated and total HIV DNA, suggesting that
SLFN11 contributes to this non-progressing phenotype.
Professor Magnus Gisslén discussed the central nervous system
(CNS) as a less well-known HIV reservoir of unknown relevance
for cure efforts. CNS infection is generally well controlled by
suppressive systemic cART, although sometimes HIV can be
detected in the cerebrospinal fluid (CSF) despite undetectable
plasma viral load. Professor Gisslén described in detail three
possible types of CSF viral escape during ART: asymptomatic,
symptomatic and secondary escape, and stressed the importance
of paying attention to new-onset CNS symptoms during effective
ART, especially during suboptimal drug adherence and with drugs
with low CNS-penetrating ability. Some 10% of asymptomatic
subjects exhibit CSF HIV RNA >50 copies/mL despite plasma RNA
<50 copies/mL, and this CSF asymptomatic escape is associated
with increased CNS inflammation. CSF blips are associated with
CNS immune activation but not with increased markers of neuronal
injury. Nevertheless, these CSF blips are not associated with
progressive disease or treatment failure [11]. An important blood
biomarker of active neuronal injury is plasma neurofilament light
protein (NFL). NFL levels are 50–100 times lower in blood
compared to CSF, although, it is still a good marker to distinguish
new onset of neurological/neurocognitive symptoms, suboptimal
penetration of ART regimens in CNS and potential harmful
activation of CNS infection by LRAs [12].
On behalf of Dr Marie-Angelique De Scheerder, Professor Linos
Vandekerckhove presented a treatment interruption study and its
effects on neuro-inflammation. In the HIV STAR study (Sequencing
after Treatment Interruption to identify the Anatomical Reservoir),
where the main objective was to identify the anatomical
compartment responsible for viral rebound duringTI, extensive blood
and tissue sampling of 12 individuals living with HIV was performed,
including blood, CSF, colon, LN, bone marrow and bronchoalveolar
lavage. Blood was collected at four time points, at baseline on cART,
day 7 after ATI, at viral rebound and after cART restart (undetectable
viral load), and CSF was sampled at baseline and during viral rebound.
No significant increase of NFL or other inflammatory markers
(nepterin/YKL-40) was detected, despite an increase in VL. These
data suggested that it is unlikely that replication in CNS has started
to a large extent early after treatment cessation. Moreover, the virus
detected in CSF was similar to virus identified in blood; Env
sequences identified in CSF after rebound were identical to the
dominant strain of rebounding virus in plasma.
Session 3
Professor Asier Sáez-Cirión opened the final session of the
symposium and presented new results from the IciStem project:
an observational study to guide and investigate the potential of
allogeneic stem cell transplantation (SCT) for HIV cure. Following
a comprehensive overview of the study design and objectives,
Professor Sáez-Cirión focused on results obtained from six specific
patients who have successfully undergone SCT and are still in active
medical follow-up. First, he showed that after SCT, five out of six
patients have an undetectable HIV latent reservoir in different
anatomical compartments (peripheral blood, ileum, CSF, LN, BM),
as measured by different reservoir quantification techniques: HIV
DNA PCR, quantitative viral outgrowth assay (qVOA) and
cell-associated unspliced HIV RNA PCR. While SCT causes a
tremendous reduction in the size of the viral reservoir, it is not
sufficient to result in HIV remission/cure. He then showed that
HIV-specific T cell responses could still be detected several years
after SCT; however, these immune responses are weak in nature
and have limited polyfunctionality. Therefore, therapies boosting
immune responses could be of interest before advancing to treatment
discontinuation. During the second part of the presentation,
Professor Sáez-Cirión presented data on the use of natural simian
immunodeficiency virus (SIV) controlling Mauritian cynomolgus
macaques as a tool to study HIV specific T cell responses. Using
this model, he demonstrated that the development of SIV-specific
CD8+T cell responses coincides with CD8 expansion in post-acute
phase control of viraemia. Furthermore, he showed that CD8 T
cells from SIV controllers show a strong capacity to suppress viral
replication ex vivo; however, this response is weak during acute
infection, suggesting that the development of the potent immune
response occurs during later stages of infection.
Professor Linos Vandekerckhove presented results of a multi-
centre, randomised, double-blind, placebo-controlled, Phase IIa
clinical trial of ABX464, which is a first-in-class antiviral drug from
Abivax. Regarding the safety assessment, only minor adverse
events such as abdominal pain and headache were observed. From
eight of fifteen participants who received the compound, a
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significant decrease in HIV reservoir size was observed between
the first day of drug administration and day 28, with a mean
decrease of 186 HIV copies per million PBMCs. No responders
were observed in the placebo group. These data illustrate that
ABX464 might have a reservoir-reducing effect; however, this
reduction did not correspond to a significant increase in the time
to viral rebound upon TI. Professor Vandekerckhove concluded
that follow-up studies involving more participants are needed as
well as studies of mechanistic actions of ABX464.
Dr Inge De Lepeleire presented data showing that a single dose
of a novel nucleoside reverse transcriptase translocation inhibitor
(NRTTI), called MK-8591, is capable of suppressing HIV replication
for at least 7 days. An open-label, single-dose study (ranging from
0.5 mg to 30 mg) was performed to evaluate the compound as
monotherapy in ART-naïve, HIV-infected subjects. The primary
study objectives were the assessment of safety and tolerability,
and the degree of VL suppression. A robust VL decline was
observed at all dose levels, even at 0.5 mg. MK-8591 was generally
safe and well tolerated, with no evidence for dose-dependent
adverse experiences. Only a limited number of mild-to-moderate
adverse events were reported. The half-life of the compound in
PBMCs was quantified at 79–128 hours, which makes the drug
interesting as a once-weekly regimen.
Professor Philip Goulder provided a comprehensive overview of
paediatric HIV infection and perspectives for HIV cure in children.
He outlined several case studies of HIV-infected infants treated
extremely early, and questioned whether HIV cure can be achieved
in paediatric patients. Professor Goulder described a cohort of
South African infants with slow or non-progressing phenotype
among which elite controller (EC) phenotypes were observed with
a frequency of 0.3–0.4%. However, unlike adults ECs, paediatric
EC phenotype is not driven by protective HLA alleles and the viral
load of paediatric ECs does not drop under the limit of detection.
To explore the underlying mechanisms of viraemic control in
infants, a second cohort of 63 HIV-infected infants was studied.
Eleven of these infants were slow/non-progressors, characterised
by a lower VL (1 log10 lower than progressors) and a higher breadth
and magnitude of the CD8+ response. He showed that unlike in
adult infection, during paediatric infection there is generation of
cytotoxic T-lymphocytes (CTL) specific to escape variants. He
postulated that HIV-specific CTLs are likely to be one component
contributing to paediatric viraemic control, but most probably other
factors, such as host genetic factors, also play a role.
Continuing on the topic of paediatric HIV infection, Dr Jean-
Christophe Beghin discussed the immunological outcome of
HIV-infected children living in South Africa upon treatment
initiation. He compared a cohort of children who started cART
within 1 year after birth (early starters cohort: ESC) with a cohort
of children who started cART at age 2 years or later (late starters
cohort: LSC). His study demonstrated that cART is highly effective
regardless of age and CD4% at treatment initiation; however, ESC
treated with a PI-based regimen achieved normal CD4% and
sustained virological suppression more often.
Dr Maria Buzon presented a comprehensive overview of
conventional and new ex vivo assays to measure the size of the
HIV latent reservoir. The first part of her talk focused on
conventional PCR-based and cell culture-based approaches,
ranging from total HIV DNA quantification by PCR to quantitative
viral outgrowth assay (qVOA). Advantages and disadvantages, as
well as technical details, were provided for each of the described
assays. In the second part of her talk, Dr Buzon discussed novel
assays to measure the latent reservoir, going from full HIV genome
sequencing to the murine viral outgrowth assay (mVOA). While
some of these novel assays seem very promising in delivering an
accurate measurement of the reservoir size, Dr Buzon concluded
that ATI is eventually the only way to determine whether the
patient is cured, making it the ultimate assay.
Mr Pieter Pannus presented correlates of viral suppressive capacity
(VSC) in cART-treated HIV-infected patients focusing on CD8+
T cell responses. Using the viral inhibition assay (VIA), he quantified
the viral suppressive capacity of CD8+ T cells obtained from a total
of 36 successfully treated HIV-positive patients and showed that
VSC can be enhanced in vitro by HIV peptide stimulation. While
the magnitude of VSC did not correlate with measures of the
reservoir size, it did correlate with IFN-γ production, PD1/CD160
co-expression and HLA-DR expression during co-culture.
Mr Basiel Cole presented analysis of virus integration site data
obtained from 10n chronically infected, long-term-treated
HIV-positive individuals. After elaborating on the importance of
clonal expansion in the maintenance of the viral reservoir, Cole
demonstrated that all but one participant showed the presence
of clonally expanded HIV-infected cells, with a mean level of ~40%
of clonality. Furthermore, he showed that integration was biased
towards genes that play a role in histone modifications, DNA repair
and DNA transcription, and that there is a clear preference for
integration in the reverse orientation with respect to the gene.
In the final talk,Ms Sofie Rutsaert opened the discussion about
whether total HIV DNA could serve as reliable marker in guidance
for therapy simplification strategies. Total HIV DNA was measured
by droplet digital PCR (ddPCR) in patient samples of two
randomised clinical trials, PROTEA and DOMONO. In a substudy
of PROTEA (NCT01448707), patients were switched to darunavir/r
monotherapy and followed for 96 weeks, and in DOMONO
(NCT02401828) patients were assigned to a dolutegravir
monotherapy arm for 48 weeks. In both studies, patients with an
undetectable viral load had a significantly lower level of total HIV
DNA in comparison to patients for whom monotherapy failed
virologically, which suggests that HIV DNA can aid in selecting
patients eligible for therapy simplification strategies.
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